Scarica l'app Stockscreener
9.75
6.44%
0.59
Dopo l'orario di chiusura:
9.75
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Is Arcus Biosciences Inc. a good long term investmentConsistent high-performance stocks - Autocar Professional
Arizona State Retirement System Purchases 5,010 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
What drives Arcus Biosciences Inc. stock priceExceptional gains - jammulinksnews.com
Arcus Biosciences Inc. Stock Analysis and ForecastTriple-digit returns - jammulinksnews.com
What analysts say about Arcus Biosciences Inc. stockExplosive earning power - jammulinksnews.com
Teacher Retirement System of Texas Has $143,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Principal Financial Group Inc. Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Is Arcus Biosciences Inc. stock a good hedge against inflationFree Stock Investment Discussion Area - Newser
Trend Tracker for (RCUS) - news.stocktradersdaily.com
how arcus biosciences inc. stock performs during market volatilityTrending Stock Alert - Newser
How Arcus Biosciences Inc. stock performs during market volatilitySafe and Smart Investment Picks - Newser
What makes Arcus Biosciences Inc. stock price move sharplyFree Expert Investment Advice - Newser
Why Arcus Biosciences Inc. stock attracts strong analyst attentionElite Stock Shortlist - Newser
Allspring Global Investments Holdings LLC Has $144,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Allspring Global Investments Holdings LLC Purchases 6,453 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Amalgamated Bank Boosts Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus wins FDA orphan status for cancer drug (RCUS:NYSE) - Seeking Alpha
Arcus Biosciences' Investigational Pancreatic Cancer Treatment Gets US FDA Orphan Drug Status - MarketScreener
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer - Nasdaq
Arcus' Pancreatic Cancer Drug Gets FDA Orphan Status as Phase 3 Trial Nears Full Enrollment - Stock Titan
Does Arcus Biosciences (NYSE:RCUS) Have A Healthy Balance Sheet? - simplywall.st
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designatio - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment - MSN
State of Alaska Department of Revenue Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
(RCUS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
GAMMA Investing LLC Buys 15,466 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: promising cancer therapy stock faces pivotal year - Investing.com
Arcus Biosciences Sees Unusually High Options Volume (NYSE:RCUS) - Defense World
Arcus Biosciences Holds Annual Stockholders Meeting - TipRanks
Arcus Biosciences Inc Inc. (RCUS) Price Performance: A Technical Analysis Perspective - investchronicle.com
Positive Signs As Multiple Insiders Buy Arcus Biosciences Stock - simplywall.st
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Comments on RCUS FY2026 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):